The FDA approved ruxolitinib (Jakafi, Incyte) for chronic graft-versus-host disease (GVHD) after failure of one or two lines of systemic therapy in adults and children ages 12 years and older.
“Nearly half of the people who develop chronic GVHD do not respond adequately to steroids—the current standard of care—making this life-threatening condition particularly challenging to treat,” noted Robert Zeiser, MD, the principal investigator of the REACH3 trial, on which the